medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2015, Number 1

<< Back Next >>

An Med Asoc Med Hosp ABC 2015; 60 (1)

Carta al editor

Cabrera-Gaytán DA, Mendoza VIL

Language: Spanish
References: 15
Page: 65-67
PDF size: 118.48 Kb.


Text Extraction

No abstract


REFERENCES

  1. Gurría-Juárez JP, Magaña-Rivero A, Jáuregui-Camargo L, Martínez-Ayala P. Tuberculosis amigdalina primaria en una paciente con artritis reumatoide bajo tratamiento con anti-FNTa (etanercept). An Med (Mex). 2014; 59 (2): 133-136.

  2. Paromita R, Halder A, Chowdhury J, Roy AK. Primary tuberculosis in soft palate: case report of a rare entity. Indian J Dermatol. 2014; 59 (4): 423. doi: 10.4103/0019-5154.135543.

  3. Secretaría de Salud. Presentación “El control de la TB en México. ¿En dónde estamos? Santiago de Querétaro, 21 de abril de 2014. No publicado.

  4. Sistema Nacional de Vigilancia Epidemiológica. Cierre oficial de casos notificados de tuberculosis en el Instituto Mexicano del Seguro Social durante 2013. No publicado.

  5. Mignogna MD, Muzio LL, Favia G, Ruoppo E, Sammartino G, Zarrelli C et al. Oral tuberculosis: a clinical evaluation of 42 cases. Oral Dis. 2000; 6 (1): 25-30.

  6. Chakravorty S, Kamal MS, Sivaswami J. Diagnosis of extrapulmonary tuberculosis by smear, culture, and PCR using universal sample processing technology. J Clin Microbiol. 2005; 43 (9): 4357-4362. doi: 10.1128/JCM.43.9.4357-4362.2005.

  7. Sarmiento OL, Weigle KA, Alexander J, Weber DJ, Miller WC. Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary tuberculosis. J Clin Microbiol. 2003; 41 (7): 3233. doi: 10.1128/JCM.41.7.3233-3240.2003.

  8. Roos, BR, van Cleeff MR, Githui WA, Kivihya-Ndugga L, Odhiambo JA, Kibuga DK et al. Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model. Int J Tuberc Lung Dis. 1998; 2 (3): 235-241.

  9. Tsenova L, O’Brien P, Holloway J, Peixoto B, Soteropoulos P et al. Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis. J Interferon Cytokine Res. 2014; 34 (9): 716-726. doi:10.1089/jir.2013.0123.

  10. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014; 91: 47-55. doi: 10.3899/jrheum.140102

  11. Xie X, Chen J, Peng Y, Gao J, Tian J, Ling G et al. Meta analysis of infection risks of anti-TNF-a treatment in rheumatoid arthritis. Medical Sciences. 2013; 38 (7): 722-736.

  12. Ke WM, Chen LS, Parng IM, Chen WW, On AW. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis. 2013; 17 (12): 1590-1595.

  13. Yamada T, Nakajima A, Inoue I, Tanaka E, Hara M et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006; 65: 1661-1663. doi: 10.1136/ard.2005.047274.

  14. Tran TN, Caspard H, Magrini F. Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis –a systematic evaluation of the literature. Open Access Rheumatology: Research and Reviews. 2013; 5: 21-32.

  15. Norma Oficial Mexicana NOM-017-SSA2-2012, para la vigilancia epidemiológica. Diario Oficial de la Federación, (19 de febrero de 2013).




2020     |     www.medigraphic.com